223 related articles for article (PubMed ID: 12678751)
1. Novel aspects of natural and modified vinca alkaloids.
Duflos A; Kruczynski A; Barret JM
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
[TBL] [Abstract][Full Text] [Related]
2. Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities.
Fahy J
Curr Pharm Des; 2001 Sep; 7(13):1181-97. PubMed ID: 11472261
[TBL] [Abstract][Full Text] [Related]
3. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
4. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
5. The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.
Montag G; Stopper H; Ngo QA; Hintzsche H
Curr Cancer Drug Targets; 2019; 19(3):222-230. PubMed ID: 29714145
[TBL] [Abstract][Full Text] [Related]
6. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
[TBL] [Abstract][Full Text] [Related]
7. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
[TBL] [Abstract][Full Text] [Related]
8. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
Zhang Y; Yang SH; Guo XL
Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
[TBL] [Abstract][Full Text] [Related]
9. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
Coderch C; Morreale A; Gago F
Anticancer Agents Med Chem; 2012 Mar; 12(3):219-25. PubMed ID: 22044006
[TBL] [Abstract][Full Text] [Related]
10. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
Kelly EB; Tuszynski JA; Klobukowski M
J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
[TBL] [Abstract][Full Text] [Related]
11. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.
Li W; Shao Y; Hu L; Zhang X; Chen Y; Tong L; Li C; Shen X; Ding J
Cancer Biol Ther; 2007 May; 6(5):787-94. PubMed ID: 17387272
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules.
Himes RH
Pharmacol Ther; 1991; 51(2):257-67. PubMed ID: 1784631
[TBL] [Abstract][Full Text] [Related]
14. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical pharmacology of vinca alkaloids.
Zhou XJ; Rahmani R
Drugs; 1992; 44 Suppl 4():1-16; discussion 66-9. PubMed ID: 1283846
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
17. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
18. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
Aparicio LM; Pulido EG; Gallego GA
Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
[TBL] [Abstract][Full Text] [Related]
19. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
Hill BT
Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
[TBL] [Abstract][Full Text] [Related]
20. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.
Martino E; Casamassima G; Castiglione S; Cellupica E; Pantalone S; Papagni F; Rui M; Siciliano AM; Collina S
Bioorg Med Chem Lett; 2018 Sep; 28(17):2816-2826. PubMed ID: 30122223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
